Actinonin

Drug Profile

Actinonin

Alternative Names: VRC 483

Latest Information Update: 30 Sep 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source; Vicuron Pharmaceuticals
  • Class
  • Mechanism of Action Angiogenesis inhibitors; Metalloprotease inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bacterial infections; Cancer

Most Recent Events

  • 30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
  • 03 Dec 1999 Preclinical development for Bacterial infections in USA (Unknown route)
  • 13 Mar 1998 A preclinical study has been added to the adverse events and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top